Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Trans-2,3-enoyl-CoA reductase (TECR) is an endoplasmic reticulum-associated enzyme encoded by the TECR gene in humans, belonging to the steroid 5-alpha reductase family. It catalyzes the final (saturation) step in microsomal long- and very long-chain fatty acid (VLCFA) elongation by reducing trans-2,3-enoyl-CoA intermediates to their saturated acyl-CoA forms using NADPH as a cofactor. TECR plays a central role in the production of saturated and monounsaturated VLCFAs, which are major constituents of sphingolipids, and participates in both lipid biosynthesis and degradation pathways, including an essential step in sphingosine degradation via the sphingosine-1-phosphate metabolic pathway. Mutations in TECR are associated with non-syndromic mental retardation, likely through disruption of neural lipid metabolism.
Catalyzes reduction of trans-2,3-enoyl-CoA to saturated acyl-CoA in fatty acid elongation; uses NADPH as electron donor; key step in very long-chain fatty acid and sphingolipid synthesis
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Trans-2,3-enoyl-CoA reductase (TECR).